Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.

The European Medicines Agenecy has noted a positive summary of opinion for the first generic combination of tenofovir/emtricitabine (Truvada).

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...